Aatur Singhi, MD PhD @PancPathologist

Pancreatic/Gastrointestinal Pathologist. T/RT ≠ medical advice Pittsburgh, PA Joined April 2016

Tweets

4K
Followers

8K
Following

5K
Likes

24K

Anirban Maitra @Aiims1742

9 hours ago

Grateful to @lustgartenfdn for supporting our 1st in human trial of a KRAS inhibitor to intercept #PancreaticCancer in high risk patients. We finally have the plausible tools (vaccines, oral KRAS inh) for cancer interception in this terrible disease. lustgarten.org/2026-lustgarte…

1 4 42 1K 4

View Details

Linghua Wang, MD, PhD @IamLinghua

a week ago

😁Thrilled to share our new study out today in @Cancer_Cell doi.org/10.1016/j.ccel… Grateful to have co-led this work with Dipen Maru, @skopetz Luisa Solis Soto @humam_kadara @RuoyanLi. Huge congratulations to Yang Liu @liuyupupupup Akshaya Jadhav, the entire team @UTMDAnderson

4 38 162 12K 55

View Details

Eric Topol @EricTopol

2 weeks ago

For treatment and outcomes for cancer, the tumor microenvironment (TME) is pivotal, but we've never had a non-invasive way to assess it. Until now, a blood test breakthrough! (<-a term I use sparingly) Pictured below, schematically, the TME surrounds the cancer cells and consists of immune cells, blood vessel (endothelial) cells, fibroblasts and matrix

13 134 619 138K 256

View Details

Rasa Valiauga, MD, PhD @RasaValiauga

2 weeks ago

First day of residency ✅ Excited to trade in my stethoscope for a microscope with the best people 🔬 @UPMCPath @UPMCPathology

2 3 50 5K 2

View Details

James Cleary @JamesClearyMD

2 weeks ago

Add NRG1 fusions to the list of targetable alterations in cholangiocarcinoma. 🔹 Zenocutuzumab is now FDA-approved for NRG1-fusion positive cholangio 🔹 RNA NGS >>> DNA NGS for detecting NRG1 fusions. Best practice: order both for all cholangio pts doi.org/10.1200/JCO-25…

3 14 27 4K 4

View Details

Aatur Singhi, MD PhD @PancPathologist

3 weeks ago

@ZhiVenFongMD @NabilWasifMD Hopefully... we have two tries with this... Global Pancreatic Cyst Guidelines and the American College of Gastroenterology guidelines.

0 0 2 54 0

View Details

Anirban Maitra @Aiims1742

3 weeks ago

Impressive review in @Cancer_Cell from an impressive set of authors: Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts cell.com/cancer-cell/fu… @IamLinghua @HHuanglab @MaraShermanLab @shouval @BiffiGiulia

3 44 140 9K 56

View Details

Oliver @Eickelberg_MD

4 weeks ago

YAY!!! Huge congrats to previous team @UMich and our entire team @PittTweet @PittDeptofMed 👏👏👏. Most importantly, all our authors, reviewers, readers and team @the_asci.

JCI insight @JCI_insight

4 weeks ago

📣We're proud to announce an increase in JCI Insight's impact factor to 6.8 (from 6.1, 2024) . Thank you authors, reviewers, and readers!

0 3 10 2K 0

0 3 11 2K 2

View Details

Denis Wirtz @deniswirtz

4 weeks ago

Great colleague Rong Fan led a team of experts at Yale, Hopkins, and UCSD to write a review on 3D multi-comics of tissues and tumors. Check it out: nature.com/articles/s4156…

2 17 80 7K 24

View Details

Eric Topol @EricTopol

4 weeks ago

That's a lot of spatial human proteomics! >13,000 proteins ~3,0000 samples 58 major tissues types 25 cancer types nature.com/articles/s4158…

9 166 502 44K 260

View Details

Arjun Chatterjee @Chatterjee_MD

a month ago

Join us in Minneapolis, MN for @CAPERpancreas #PacreasFEST26 We are debating pancreas cyst fluid analysis prior to surgery when worrisome features are present on imaging! @PancPathologist #DavidWeinberg @NatPancFdn @apapancreas @MaisamHaijaMD @PittGILiverNutr @CCF_GIFellows

0 3 21 1K 0

View Details

Anirban Maitra @Aiims1742

a month ago

The House Appropriations Committee passed its version of the FY27 spending bill, including an increase of $110 million compared to the current year’s budget for @theNCI 👏🏽👏🏽 From @TheCancerLetter cancerletter.com/capitol-hill/2… The Senate will now take up its version of appropriations.

1 11 54 5K 1

View Details

Anirban Maitra @Aiims1742

a month ago

Papillary adenocarcinoma of head of pancreas, with metastases to common bile duct and lung @NEJM 1946 Case records of MGH. Probably one of the first descriptions of what we would now call as #PancreaticCancer arising in a main duct intraductal papillary mucinous neoplasm (IPMN).

1 2 17 2K 4

View Details

Denis Wirtz @deniswirtz

a month ago

Hopkins will provide $280M in mid-size and large grants to support faculty for 2 years (1) $160M for all life scientists (from basic to translation) (2) $120M for all science and engineering. This cannot replace federal funding, not even close, but it helps.

5 52 315 25K 35

View Details

Rong Fan @RongFan8

a month ago

🤩 spatial panoramic in vivo CRISPR screen via Perturb-DBiT 🤩 Excited to share our collaborative work with @sidichen lab and many outstanding collaborators, now published in Nature Biotechnology! nature.com/articles/s4158…

3 62 244 19K 80

View Details

PanCAN @PanCAN

a month ago

PanCAN's Chief Scientific and Medical Officer, Dr. @ABerkenblit, shares, "I know that in the years to come, we'll look back on this year's #ASCO26 meeting as marking the beginning of a new era for patients with pancreatic cancer. As a long-standing American Society of Clinical Oncology (ASCO) member, it was a privilege this year to attend alongside my colleagues from Pancreatic Cancer Action Network, knowing the pivotal role PanCAN played to get us to this historic moment, and that the community is looking to PanCAN to help us all make good on the promise that RAS therapies hold for patients with pancreatic cancer. Unprecedented indeed are the Phase 3 data for #daraxonrasib, a RAS-targeted therapy developed by Revolution Medicines and presented by Dr. Brian Wolpin. These highly anticipated data were received with wild enthusiasm — a standing ovation! — from the ASCO community. Overall survival and progression-free survival were ~doubled, and overall response rate was ~tripled with daraxonrasib compared with chemotherapy in patients with previously treated metastatic pancreatic cancer, with all subgroups benefiting. Importantly, quality of life and pain were improved, so that patients not only live longer, but also feel better — just what we want from new therapies. Optimal management of side effects, including rash and mouth sores, is paramount to maximize the benefit — and PanCAN Patient Services is ready to embrace the educational needs!" Learn more about the additional data released on daraxonrasib and this significant advance for #pancreaticcancer treatment at 🔗 pcan.at/rjul9sza.

0 8 18 949 1

View Details

Dr. Patrick Hwu @PatrickHwuMD

2 months ago

Important research shared by Dr. Diwakar Davar (@diwakardavar) at #ASCO26 on a PRAME-directed T-cell therapy for patients with advanced melanoma. The research showed meaningful responses in patients with limited treatment options, highlighting a promising approach for difficult-to-treat melanoma. @UPMCHillmanCC #ASCO26 #MoffittASCO26

0 3 20 1K 1

View Details

Aatur Singhi, MD PhD @PancPathologist

2 months ago

@CLuchini10 @VolkanAdsay @Chris_Heaphy Excellent work @CLuchini10!

0 0 1 429 0

View Details

Claudio Luchini @CLuchini10

2 months ago

Multi-omics approaches are unravelling the complex biological landscape of pancreatic #NETs Building on this collective effort, we have integrated this remarkable body of knowledge into a comprehensive overview rdcu.be/flQyn @PancPathologist @VolkanAdsay @Chris_Heaphy

1 3 9 1K 0

View Details

Adam Feuerstein ✡️ @adamfeuerstein

2 months ago

Incredible #ASCO26 moment. Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD